Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Propanc Biopharma Inc (PPCB : OTC)
 
 • Company Description   
Propanc Biopharma, Inc. is a healthcare company. It focuses on the development of cancer treatments for pancreatic, ovarian and colorectal cancer primarily in Australia. The Company's products include PRP and PRP-DCM. Propanc Biopharma, Inc., formerly known as Propanc Health Group Corporation, is based in Camberwell, Australia.

Number of Employees: 2

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.01 Daily Weekly Monthly
20 Day Moving Average: 3,275,162 shares
Shares Outstanding: 74.99 (millions)
Market Capitalization: $0.56 (millions)
Beta: 1.49
52 Week High: $0.15
52 Week Low: $0.01
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -33.04% -26.63%
12 Week -62.69% -59.51%
Year To Date -82.96% -79.73%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
302 6 BUTLER STREET
-
CAMBERWELL,C3 3124
AUS
ph: 61 03 9882 6723
fax: 61 03 9882 9969
irteam@propanc.com http://www.propanc.com
 
 • General Corporate Information   
Officers
James Nathanielsz - Chief Executive Officer; Chairman; Chief Financial
Julian Kenyon - Director
Josef Zelinger - Director
- - -
- - -

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74346N404
SIC: 2834
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 05/20/22
Share - Related Items
Shares Outstanding: 74.99
Most Recent Split Date: 11.00 (0.00:1)
Beta: 1.49
Market Capitalization: $0.56 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/20/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 95.56%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -4,659.79
09/30/21 - -5,811.36
Current Ratio
03/31/22 - -
12/31/21 - 0.03
09/30/21 - 0.02
Quick Ratio
03/31/22 - -
12/31/21 - 0.03
09/30/21 - 0.02
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -0.05
09/30/21 - -0.05
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©